Effect of clozapine and adjunctive high-dose glycine in treatment- resistant schizophrenia

American Journal of Psychiatry

Volumn 156, Issue 1, 1999, Pages 145-147

  Potkin, Steven G ^a   Jin, Yi ^b   Bunney, Blynn G ^b   Costa, Jerome ^b   Gulasekaram, Bala ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLYCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032955821     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.1.145     Document Type: Article

References (17)

1. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308
2. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM: A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12:1-13
3. Bunney BG, Bunney WE Jr, Carlsson A: Schizophrenia and glutamate, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 1205-1214
4. Costa J, Khaled E, Sramek J, Bunney WE Jr, Potkin SG: An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 1990; 10:71-72
5. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D: Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169:610-617
6. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P: Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151:1234-1236
7. Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulaskaram B: Glycine in the treatment of schizophrenia: theory and preliminary results, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press, 1992, pp 179-188
8. Rosse RB, Theut S, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI: Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label pilot study. Clin Neuropharmacol 1989; 12:416-424
9. Waziri R: Glycine therapy of schizophrenia (letter). Biol Psychiatry 1988; 23:210-211
10. Heresco-Levy U, Silipo G, Javitt DC: Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996; 32: 731-740
11. Goff DC, Tsai G, Manoach DS, Coyle JT: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152:1213-1215
12. Cascella NG, Macciardi F, Cavallini C, Smeraldi E: D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open label study. J Neural Transm 1994; 95:105-111
13. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
14. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
15. Levine J, Schooler NR: SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22:343-381
16. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT: D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153:1628-1630
17. Hay WL: Statistics. Fort Worth. Tex, Holt, Rinehart & Winston, 1988